In this episode, Medicom’s correspondent covers 6 presentations from the annual meeting of the American College of Cardiology (ACC 2023), held in New Orleans, LA, USA, from 4-6 March 2023.
The topics discussed are:
- Bempedoic acid in statin-intolerant patients at high cardiovascular risk
Among statin-intolerant patients, treatment with bempedoic acid lowered low-density lipoprotein cholesterol (LDL-C) and effectively reduced the risk of major adverse cardiovascular events. This was established in the phase 3, double-blind, randomised, placebo-controlled CLEAR Outcomes trial. - Inflammation stronger predictor of MACE than cholesterol levels
A collaborative analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials showed that residual inflammatory risk is a better predictor of future major adverse cardiovascular events, cardiovascular death, and all-cause mortality than residual cholesterol risk in statin-treated patients. Thus, targeting low-density lipoprotein cholesterol alone is unlikely to completely reduce atherosclerotic risk. - Transcatheter repair for patients with tricuspid regurgitationTricuspid transcatheter edge-to-edge repair reduced the severity of tricuspid regurgitation at 1 year and was associated with an improved quality of life in patients with severe tricuspid regurgitation. These were the main findings of the prospective, randomised TRILUMINATE trial.
- RENOVATE-COMPLEX-PCI results support intravascular-guided PCI for complex lesionsThe RENOVATE-COMPLEX-PCI trial showed that percutaneous coronary intervention (PCI) guided by intravascular imaging for complex coronary artery lesions was associated with a lower risk of death than angiography-guided PCI.
- Minimally invasive versus conventional sternotomy for mitral valve repair
The best surgical approach for mitral valve repair is subject to wide debate. Findings from the randomised UK Mini Mitral trial showed similar improvement in physical activity, surgical outcomes and quality of life in patients undergoing minimally invasive and conventional surgical techniques for mitral valve repair. - Sotatercept improves exercise capacity in patients with PAHSotatercept is a fusion protein that traps activins and growth differentiation factors involved in pulmonary arterial hypertension (PAH). Adding this novel first-in-class agent to background PAH therapy led to significant and clinically relevant improvements in exercise capacity and other endpoints in the placebo-controlled STELLAR trial.
Enjoy listening!
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
DDD 2023 Highlights Podcast »
« Letter from the Editor Next Article
DDD 2023 Highlights Podcast »
Table of Contents: ACC 2023
Featured articles
Pulmonary Arterial Hypertension
Sotatercept improves exercise capacity in patients with PAH
Fixed-dose macitentan plus tadalafil superior to either agent alone in PAH
Coronary Revascularisation
Immediate complete revascularisation non-inferior to staged complete revascularisation
RENOVATE-COMPLEX-PCI results support intravascular-guided PCI for complex lesions
Heart Failure and Cardiomyopathy
No need to restrict vigorous exercise in selected HCM patients?
No difference in CV outcomes between PET or CMR and SPECT
Interventional and Structural Cardiology
Benefits of MitraClip sustained to 5 years in COAPT trial
Transcatheter repair for patients with tricuspid regurgitation
Minimally invasive versus conventional sternotomy for mitral valve repair
Durable benefits of TAVR versus surgical aortic valve replacement in aortic stenosis patients
PCI not better than GDMT in severe ischaemic cardiomyopathy
Prevention
Anticoagulation in non-critically ill hospitalised COVID patients
Statins associated with reduced heart dysfunction from anthracyclines
Multifaceted strategy improves prescription of therapies for diabetes and ASCVD
Dyslipidaemia
Bempedoic acid benefits statin-intolerant patients at high cardiovascular risk
Evolocumab improves coronary plaque morphology in stable CAD
Inflammation stronger predictor of MACE than cholesterol levels
Oral PCSK9 inhibitor significantly lowers LDL-C
Miscellaneous
Baxdrostat in patients with uncontrolled hypertension
Hormone therapy for gender dysphoria associated with increased CV risk
Pulsed-field ablation appears safe and effective for atrial fibrillation
Key correlates of incident dementia identified in the MESA study
Related Articles
March 28, 2024
Custom content article
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com